Ignite Creation Date:
2024-05-05 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00150748
Status:
COMPLETED
Last Update Posted:
2020-07-29
First Post:
2005-09-06
Brief Title:
Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy
Sponsor:
UCB Pharma SA
Organization:
UCB Pharma
Study Overview
Official Title:
An Open-label Multicenter Follow-up Study to Evaluate the Safety and Efficacy of Levetiracetam LEV Oral Tablets of 166 250 or 500 mg bid at Individualized Doses up to a Maximum of 4000 mgDay or 80 mgkgDay for Children and Adolescents Less Than 50 kg in Children 4 Years Old Adolescents and Adults Suffering From Primary Generalized Seizures
Status:
COMPLETED
Status Verified Date:
2020-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
An open-label follow-up study to evaluate the safety and efficacy of levetiracetam LEV in children 4 years old adolescents and adults suffering from primary generalized seizures
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2004-001997-13 | EUDRACT_NUMBER | None | None |